Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Canaccord Genuity's Whitney Ijem raised their price target on Palvella Therapeutics (NASDAQ: PVLA) by 64.4% from $90 to $148 on 2025/11/14. The analyst maintained their Strong Buy rating on the stock.

Palvella Therapeutics reported its Q3 2025 earnings.

According to Whitney, the print was "ordinary," indicating everything is going as planned until top-line Ph2 CVM data is reported in mid-2025/12, and top-line Ph3 MLM data is released in Q1 2026.

Among the most noteworthy recent developments, according to the analyst, was the introduction of a new pharmaceutical candidate, QTORIN pitavastatin, for the treatment of DSAP (Disseminated Superficial Actinic Porokeratosis).

Earnings Report

For Q3 2025, Palvella Therapeutics reported:

• Loss per share of $1.03, compared to Q3 2024’s loss per share of $3.94.

Management did not provide EPS and revenue guidance in its press release.

Founder & CEO Wes Kaupinen commented: “As we enter year-end 2025, Palvella is now advancing innovative QTORIN™-derived therapies for four serious, rare skin diseases, each lacking a single FDA-approved therapy, allowing us to potentially be first for each of these deserving rare disease communities.

“Our lead product candidate, QTORIN™ rapamycin, continues to demonstrate its potential as a pipeline-in-a-product for mTOR-driven skin diseases, with a planned Phase 2 top-line readout in cutaneous venous malformations expected in mid-2025/12. 

“This will be followed by a Phase 3 topline readout in microcystic lymphatic malformations which we anticipate in Q1 2026. 

“Overall, we anticipate the next 18 months will be a catalyst-rich period highlighted by our objective to advance QTORIN™ rapamycin toward its first potential regulatory approval, with a steady flow of clinical, pre-commercialization, regulatory, and indication expansion milestones for QTORIN™ rapamycin and our additional QTORIN™ pipeline programs expected.

“Achievement of these milestones will advance our vision of becoming the leading biopharmaceutical company addressing serious, rare skin diseases with no FDA-approved therapies.”